ETF Preview: ETFs Mixed to Lower, Futures Higher Ahead of Alibaba Debut

Active broad-market exchange-traded funds in Thursday's regular session:

SPDR S&P 500 ( SPY ): +0.53%

iShares S&P 500 ( IVV ): +0.52%

PowerShares QQQ ( QQQ ): +0.75%

iShares Russell 2000 ( IWM ): +0.96%

iShares Russell 1000 Growth ( IWF ): +0.41%

iShares MSCI Emerging Markets Index (EEM): +0.14%

United States Oil Fund (USO): -1.11%

SPDR Gold Shares (GLD): +0.20%

Select Financial Sector SPDRS (XLF): +0.98%

Friday's Pre-Market Most Active:

SPY, -0.18%

XLF, -0.04%

EEM, +0.25%

GDX, +0.04%

QQQ, +0.09%

Broad Market Indicators

Broad-market exchange-traded funds, including SPY, IWM, IVV and others, were mixed to lower. Actively traded PowerShares QQQ ( QQQ ) is up 0.09%.

Meanwhile, U.S. stock futures were pointing to a higher open as market sentiment got a boost ahead of the debut of China's Alibaba (BABA) which priced its public offering last night with a $68 per share price tag, near the top of its projected price range. With this IPO and Apple's (AAPL) launch of its new smart phone, tech stocks could be in for active trading in this Friday's regular session.

Power Play: Technology

Technology Select Sector SPDR ETF (XLK), iShares Dow Jones US Technology ETF (IYW), iShares S&P North American Technology ETF (IGM) and iShares S&P North American Technology-Software Index (IGV) were inactive. SPDR S&P International Technology Sector ETF (IPK) was also unchanged.

Semiconductor ETFs SPDR S&P Semiconductor (XSD) and Semiconductor Sector Index Fund (SOXX) were also flat.

Apple Inc. (AAPL), which is gearing up to launch its new iPhone Friday, has had its price target raised by analysts at Cowen and Company to $110 from $106 a share. The firm maintained its outperform rating on the stock. Shares are up 0.26% in pre-market trading .

Winners and Losers


Select Financial Sector SPDRs (XLF) was down 0.04%. Direxion Daily Financial Bull 3X shares (FAS) was up 0.62% while its bearish counterpart, FAZ was down 0.71%.

Blackstone Mortgage Trust (BXMT) was down 2.36% after the real estate finance company said it priced an offering of 8 million common shares to raise $222.8 million, implying a price of $27.85 a share, a 3% discount to Thursday's close.


Dow Jones U.S. Energy Fund (IYE) and Energy Select Sector SPDR (XLE) were unchanged in pre-market trading.

Total S.A. (TOT) said Friday it received an offer from France-based chemical company Arkema to buy its affiliate Bostik, a global adhesives company. The offer values Bostik at about $2.25 billion, equal to 11 times the company's EBITDA. Total said it granted the French group an exclusivity period to pursue the offer, and that the offer will be presented to relevant employee representatives.


Crude was down 0.39%. United States Oil Fund (USO) was down 1.54%. Natural gas futures was down 0.7%. United States Natural Gas Fund (UNG) was down 3.29%.

Gold was down 0.28% while silver was down 0.31% . Among rare metal funds, SPDR Gold Trust (GLD) was down 0.14% while iShares Silver Trust (SLV) was down 0.39%.


Consumer Staples Select Sector SPDR (XLP) , iShares Dow Jones US Consumer Goods (IYK) and Vanguard Consumer Staples ETF (VDC) were inactive.

Tesla (TSLA) was down 1.07% after the company said it has teamed up with Chinese phone manufacturer Huawei to develop a new Android-based app that will allow Tesla vehicle owners to control their cars, StreetInsider reported citing Huawei spokesperson Yi Linna. The new app will allow owners to unlock and start their vehicles, control the A/C unit and lights, as well as other functions. The app will be compatible with the Huawei Honor 6 smartphone and will work over any 4G connection.


Health Care SPDR (XLV) , Vanguard Health Care ETF (VHT) and iShares Dow Jones US Healthcare (IYH) were flat. Biotechnology fund iShares NASDAQ Biotechnology Index (IBB) was also unchanged.

Gilead Sciences (GILD) was up 1.27% in Friday's pre-market after it announced the European Commission gave a green light to sell a GILD drug for blood cancer. The drug is Zydelig (idelalisib), a twice-a-day pill for two incurable blood cancers, chronic lymphocytic leukemia, and follicular lymphoma.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 All rights reserved. Unauthorized reproduction is strictly prohibited.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics